{
    "clinical_study": {
        "@rank": "50251", 
        "arm_group": [
            {
                "arm_group_label": "Limited Scleroderma"
            }, 
            {
                "arm_group_label": "Diffuse Scleroderma"
            }
        ], 
        "biospec_descr": {
            "textblock": "-  5 mL blood draw for LOXL2 testing\n\n        -  2 Punch Skin Biopsies (one near the scleroderma lesion, the other from normal skin)"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "To treat patients with scleroderma by blocking the expression of LOXL2.  The investigators\n      first need to confirm (through observation) that LOXL2 is overexpressed in disease."
        }, 
        "brief_title": "A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Limited Scleroderma", 
            "Diffuse Scleroderma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Scleroderma, Systemic", 
                "Scleroderma, Diffuse", 
                "Scleroderma, Localized", 
                "Scleroderma, Limited", 
                "CREST Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Scleroderma is a chronic skin-hardening disease. There are two types of scleroderma.  The\n      first type is called limited cutaneous scleroderma, where disrupted blood flow causes skin\n      discoloration and sometimes patients experience high blood pressure in their arteries.  The\n      second type is called diffuse cutaneous scleroderma and it is much more aggressive,\n      affecting a larger area of skin causing organ damage.  This study will determine if the\n      disease is associated with an elevated expression of LOXL2 levels in tissue samples from\n      patients."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Over 18 years of age\n\n          -  Documented diagnosis of scleroderma\n\n          -  Willing and able to provide written informed consent\n\n        Exclusion Criteria:\n\n          -  Use of experimental therapies within 28 days prior to Screening.\n\n          -  Aspirin use > 81 mg daily within 1 week prior to Screening.\n\n          -  Any lab abnormality or concurrent medical condition that, in the opinion of the\n             investigator would make the patient ineligible for the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Adult subjects with documented diagnoses of scleroderma will be enrolled into one of two\n        cohorts, depending upon the subject's diagnosis"
            }
        }, 
        "enrollment": {
            "#text": "29", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01881529", 
            "org_study_id": "GS-US-321-0108"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "limited scleroderma", 
            "diffuse scleroderma", 
            "Sclerosis", 
            "Progressive", 
            "Limited"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Darlinghurst", 
                    "country": "Australia", 
                    "state": "New South Wales", 
                    "zip": "2010"
                }, 
                "name": "St Vincent's Centre for Applied Medical Research"
            }
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_groups": "2", 
        "official_title": "A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma", 
        "overall_official": {
            "affiliation": "Gilead Sciences", 
            "last_name": "Bittoo Kanwar, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Australia: Human Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Summarized the number and percentage of subjects with elevated LOXL2 levels", 
            "safety_issue": "No", 
            "time_frame": "Baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01881529"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}